2R3Q

Crystal Structure of Cyclin-Dependent Kinase 2 with inhibitor


Experimental Data Snapshot

  • Method: X-RAY DIFFRACTION
  • Resolution: 1.35 Å
  • R-Value Free: 0.202 
  • R-Value Work: 0.181 
  • R-Value Observed: 0.182 

wwPDB Validation   3D Report Full Report


This is version 1.1 of the entry. See complete history


Literature

Structure-guided discovery of cyclin-dependent kinase inhibitors.

Fischmann, T.O.Hruza, A.Duca, J.S.Ramanathan, L.Mayhood, T.Windsor, W.T.Le, H.V.Guzi, T.J.Dwyer, M.P.Paruch, K.Doll, R.J.Lees, E.Parry, D.Seghezzi, W.Madison, V.

(2008) Biopolymers 89: 372-379

  • DOI: 10.1002/bip.20868
  • Primary Citation of Related Structures:  
    2R3J, 2R3I, 2R3H, 2R3G, 2R3F, 2R3R, 2R3Q, 2R3P, 2R3O, 2R3N

  • PubMed Abstract: 
  • CDK2 inhibitors containing the related bicyclic heterocycles pyrazolopyrimidines and imidazopyrazines were discovered through high-throughput screening. Crystal structures of inhibitors with these bicyclic cores and two more related ones show that al ...

    CDK2 inhibitors containing the related bicyclic heterocycles pyrazolopyrimidines and imidazopyrazines were discovered through high-throughput screening. Crystal structures of inhibitors with these bicyclic cores and two more related ones show that all but one have a common binding mode featuring two hydrogen bonds (H-bonds) to the backbone of the kinase hinge region. Even though ab initio computations indicated that the imidazopyrazine core would bind more tightly to the hinge, pyrazolopyrimidines gain an advantage in potency through participation of N4 in an H-bond network involving two catalytic residues and bridging water molecules. Further insight into inhibitor/CDK2 interactions was gained from analysis of additional crystal structures. Significant gains in potency were obtained by optimizing the fit of hydrophobic substituents to the gatekeeper region of the ATP binding site. The most potent inhibitors have good selectivity.


    Related Citations: 
    • Versatile templates for the development of novel kinase inhibitors: Discovery of novel CDK inhibitors.
      Dwyer, M.P., Paruch, K., Alvarez, C., Doll, R.J., Keertikar, K., Duca, J., Fischmann, T.O., Hruza, A., Madison, V., Lees, E., Parry, D., Seghezzi, W., Sgambellone, N., Shanahan, F., Wiswell, D., Guzi, T.J.
      (2007) Bioorg Med Chem Lett 17: 6216

    Organizational Affiliation

    Schering-Plough Research Institute, Kenilworth, NJ 07033, USA.



Macromolecules
Find similar proteins by:  (by identity cutoff)  |  Structure
Entity ID: 1
MoleculeChainsSequence LengthOrganismDetailsImage
Cell division protein kinase 2A299Homo sapiensMutation(s): 0 
Gene Names: CDK2CDKN2
EC: 2.7.11.22
Find proteins for P24941 (Homo sapiens)
Explore P24941 
Go to UniProtKB:  P24941
NIH Common Fund Data Resources
PHAROS  P24941
Protein Feature View
Expand
  • Reference Sequence
Small Molecules
Ligands 1 Unique
IDChainsName / Formula / InChI Key2D Diagram3D Interactions
5SC
Query on 5SC

Download CCD File 
A
3-((3-bromo-5-o-tolylpyrazolo[1,5-a]pyrimidin-7-ylamino)methyl)pyridine 1-oxide
C19 H16 Br N5 O
DXUJQXZHHGJMFM-UHFFFAOYSA-N
 Ligand Interaction
Modified Residues  1 Unique
IDChainsTypeFormula2D DiagramParent
CSD
Query on CSD
AL-PEPTIDE LINKINGC3 H7 N O4 SCYS
Experimental Data & Validation

Experimental Data

  • Method: X-RAY DIFFRACTION
  • Resolution: 1.35 Å
  • R-Value Free: 0.202 
  • R-Value Work: 0.181 
  • R-Value Observed: 0.182 
  • Space Group: P 21 21 21
Unit Cell:
Length ( Å )Angle ( ˚ )
a = 53.09α = 90
b = 70.99β = 90
c = 71.92γ = 90
Software Package:
Software NamePurpose
DENZOdata reduction
SCALEPACKdata scaling
PDB_EXTRACTdata extraction
BUSTER-TNTrefinement

Structure Validation

View Full Validation Report



Entry History 

Deposition Data

Revision History 

  • Version 1.0: 2008-01-22
    Type: Initial release
  • Version 1.1: 2011-07-13
    Changes: Version format compliance